Turning KRAS into a Molecular Trigger: Covalent-Induced Drug Conjugates for Conditional Tubulin Poisoning
Authors: Renner, Anna C; Kargbo, Robert B
Source journal: ACS medicinal chemistry letters (2026-11-12)
DOI: 10.1021/acsmedchemlett.6c00531
Abstract
Covalent-induced drug conjugates introduce a provocative precision-oncology strategy: mutant KRAS serves not merely as the therapeutic target but as the molecular trigger for drug release. By coupling KRAS(G12C) recognition to intracellular release of potent tubulin inhibitors, this strategy seeks to convert oncogene engagement into localized cytotoxicity while limiting systemic payload exposure.
Related topics
Related open access articles
- Emerging mycotoxins in botanicals: benefit and risk
- A Brief Review on Core/shell Quantum Dots
- In vitro cytotoxicity studies on galactosylated chitosan nanoparticles for the delivery of oridonin to liver
- Separation of Six Lupane-Type Triterpenoid Saponins from Leaves of Acanthopanax gracilistylus by HSCCC with Preparative-HPLC
- Chemical characterization of polyphenol extracts from Andean and industrial Solanum tuberosum tubers and their cytotoxic activity on human hepatocarcinoma cells
- Effects of Stresses on the Growth and Cytotoxicity of Shiga-Toxin Producing Escherichia coli in Ground Beef and Spinach
Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.